Most COVID-19 research focuses on hospitalized patients, leaving the impact of prior oral anticoagulation (OAC) therapy before admission understudied.
Analyzing data from the HOPE COVID-19 Registry, the study compared outcomes between hospitalized patients who had or hadn’t used OAC prior to their admission.
Results indicated that patients on prior OAC faced a higher risk of mortality and adverse outcomes than those without OAC, with no significant differences between types of OAC used (VKAs vs. DOACs).